Vosevi
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of adult patients with chronic HCV infection without cirrhosis or compensated cirrhosis (Child-Pugh A) who have:
- Genotype 1, 2, 3, 4, 5 or 6 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor
- Genotype 1a or 3 infection and have been previously treated with sofosbuvir without an NS5A inhibitor
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of adult patients with chronic HCV infection without cirrhosis or compensated cirrhosis (Child-Pugh A) who have:
- Genotype 1, 2, 3, 4, 5 or 6 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor
- Genotype 1a or 3 infection and have been previously treated with sofosbuvir without an NS5A inhibitor
There's more to see -- the rest of this entry is available only to subscribers.